Semaglutide: A High-Growth Market Segment Semaglutide is a GLP-1 analog that has rapidly become a blockbuster drug for type 2 diabetes and obesity, with growing use in cardiovascular risk reduction.

VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), is pleased to announce the launch of a feasibility study for the ...

What happens if you stop GLP-1 weight loss injections like semaglutide and tirzepatide? Dr Bernard Tan from Bay Medical ...

More than 20 million people globally are injecting themselves with GLP-1s... Weight-loss pills will only see that explode ...

Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy ...

Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks.

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

How to Inject Wegovy Pen: A Step-by-Step Guide. This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Wegovy (semaglutide) is approved by the U.S. Food and Drug Administration (FDA ...

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...

Semaglutide: A High-Growth Market Segment Semaglutide is a GLP-1 analog that has rapidly become a blockbuster drug for type 2 diabetes and obesity, with growing use in cardiovascular risk reduction.

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.